医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Nihon Kohden Supports Epilepsy Research Funding

2014年10月08日 AM12:00
このエントリーをはてなブックマークに追加


 

IRVINE, Calif.

For the sixth consecutive year, Nihon Kohden America Inc., a market leader in patient monitoring, sleep assessment, neurology and cardiology instrumentation, has auctioned off one of its EEG-1200A machines to benefit the American Epilepsy Society’s (AES) clinical and basic research fellowships. This year’s auction closed today with a winning bid of $23,263.75 from Dignity Health Neurological Institute of Northern California. Nihon Kohden will donate 100 percent of the auction proceeds to the AES, and will present its donation on December 6 at 1:00 p.m. during the Society’s annual meeting in Seattle.

“The impact of encouraging clinical and basic scientists at the launch of their careers is a strategic priority for AES, and this impact is felt far into the future,” noted Elson So, M.D., president, American Epilepsy Society. “AES is proud of its six-year partnership with Nihon Kohden. Their support has been a critical part of our ability to provide fellowships year after year and develop generations of researchers.”

“At the Dignity Health Neurological Institute of Northern California, we provide high quality care to patients with complex neurological conditions in our region,” said Edwin Cruz, MD, medical director of Epilepsy Services. “We are excited that we can offer our patients state-of-the-art neurodiagnostic testing and comprehensive epilepsy treatment.”

Nihon Kohden’s support of AES is part of the organization’s fundraising efforts to support the society’s educational, research and training offerings. Proceeds from the auction will be designated to support post-doctoral fellowships and early career grants awarded by the Lennox & Lombroso Trust and a clinical research training fellowship awarded by the Susan S. Spencer Fund.

“It is an honor for us to continue to support AES with research funds that directly contribute to improving the lives of those with epilepsy,” said Kathy Hart, vice president of Nihon Kohden America’s Neurology Business group. “Founded in 1951, Nihon Kohden Corporation’s mission has always been to improve the quality of life through advanced medical technology. Advancing the care and treatment of people with epilepsy is a passion we share with both the AES and Dignity Health Neurological Institute of Northern California.”

For more information, please visit www.nkusa.com.

About Nihon Kohden America

Nihon Kohden America was founded in 1979 as a wholly-owned subsidiary of Nihon Kohden Corporation, Japan (founded in 1951). Nihon Kohden is a market leader in patient monitoring, sleep assessment, neurology and cardiology instrumentation. Its products are distributed to hospitals, physician’s practices, mobile services, and outpatient and surgery centers throughout North America. For more than 60 years, health care providers worldwide have relied on the quality and reliability of Nihon Kohden’s comprehensive and innovative line of neurodiagnostic and monitoring instrumentation to aid in the diagnosis and treatment of patients.

Nihon Kohden’s long legacy in EEG diagnostics and monitoring continues with the EEG-1200, which combines EEG, long-term epilepsy, cEEG ICU monitoring and sleep testing for the most flexible and comprehensive recording system available today. More information about Nihon Kohden and EEG-1200A technology can be found at www.nkusa.com.

About the American Epilepsy Society (AES)

The American Epilepsy Society (AES) is a non-profit medical and scientific society. Our individual members are professionals engaged in both research and clinical care for people with epilepsy from private practice, academia and government. For more than 75 years, AES has been unlocking the potential of the clinical and research community by creating a dynamic global forum where professionals can share, learn and grow. AES champions the use of sound science and clinical care through the exchange of knowledge, by providing education and by furthering the advancement of the profession.

CONTACT

Lages & Associates
Stephanie Olsen, 949-453-8080
stephanie@lages.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表